Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : STADA Arzneimittel
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation...
Brand Name : Ximluci
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : STADA Arzneimittel
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.
Brand Name : Xcimzane
Molecule Type : Large molecule
Upfront Cash : $8.0 million
February 07, 2022
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 13, 2021
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane® (Ranibizumab) Biosimilar Product
Details : The Xplore trial, which was started in 2019, is intended to study the biosimilarity of Xlucane as compared to Novartis’s Lucentis® in wet age-related macular degeneration (AMD).
Brand Name : Xlucane
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 23, 2020
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?